RagD gene expression and NRF2 mutations in lung squamous cell carcinomas

RJ GinsbergMK KrisJG ArmstrongCancer of the lungPrinciples and Practice of OncologyVT DeVita JrS HellmanSA Rosenberg4th editionLippincottPhiladelphia6736821993

A JemalR SiegelE WardCancer statistics, 2009Ca Cancer J Clin59225249200910.3322/caac.20006

X ZhouM TanV Stone HawthorneActivation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancersClin Cancer Res1067796788200410.1158/1078-0432.CCR-04-011215501954

MA BjornstiPJ HoughtonThe TOR pathway: target for cancer therapyNat Rev Cancer4335348200410.1038/nrc1362

EB BordersC BivonaPJ MedinaMammalian target of rapamycin: biological function and target for novel anticancer agentsAm J Health Syst Pharm6720952106201010.2146/ajhp10002021116000

D LiuY HuangB ChenActivation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinomaCancer11737633773201110.1002/cncr.2595921387259

K GatelyB Al-AlaoT DhillonOverexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification studyLung Cancer75217222201210.1016/j.lungcan.2011.06.01221802763

Y SancakTR PetersonYD ShaulThe Rag GTPases bind raptor and mediate amino acid signaling to mTORC1Science32014961501200810.1126/science.115753518497260

T ShibataS SaitoA KokubuGlobal downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathwayCancer Res7090959105201010.1158/0008-5472.CAN-10-038421062981

LM SolisC BehrensW DongNrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic featuresClin Cancer Res1637433753201010.1158/1078-0432.CCR-09-335220534738

H SasakiY HikosakaK OkudaNFE2L2 gene mutation in male Japanese squamous cell carcinoma of the lungJ Thorac Oncol5786789201010.1097/JTO.0b013e3181db3dd320421815

T ShibataT OhtaKI TongCancer related mutations in Nrf2 impair its recognition by Keap1-Clu3 E3 ligase and promote malignancyProc Natl Acad Sci USA1051356813573200810.1073/pnas.080626810518757741

Y HuY JuD LinMutation of the Nrf2 gene in non-small cell lung cancerMol Biol RepOct12011(Epub ahead of print).

XM MaJ BlenisMolecular mechanisms of mTOR-mediated translational controlNat Rev Mol Cell Biol10307318200910.1038/nrm267219339977

E KimP Goraksha-HicksL Liregulation of TORC1 by Rag GTPases in nutrient responseNat Cell Biol10935945200810.1038/ncb175318604198

K ItohT ChibaS TakahashiAn Nef2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elementsBiochem Biophys Res Commun236313322199710.1006/bbrc.1997.69439240432

TH RushmoreAN KongPharmacogenomics, regulation and signaling pathways of phase I and II detoxifying enzymesCurr Drug Metab3481490200210.2174/138920002333717112369894

T NgyyenCS YangCB PickettThe pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stressFree Radic Biol Med37433441200410.1016/j.freeradbiomed.2004.04.03315256215

A SinghS Boldin-AdamskyRK ThimmulappaRNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapyCancer Res6879757984200810.1158/0008-5472.CAN-08-140118829555

T ArisawaT TaharaT ShibataNrf2 gene promoter polymorphism and gastric carcinogenesisHepatogastroenterology55750754200818613447

GL SemenzaTargeting HIF-1 for cancer therapyNat Rev Cancer3721732200310.1038/nrc1187

J ZhouT ScmidS SchnitzerTumor hypoxia and cancer progressionCancer Lett2371021200610.1016/j.canlet.2005.05.028

L WangW YueL ZhangmTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistrySurg TodayNov302011(Epub ahead of print).